Simple blood test could replace biopsies for cancer gene testing
NCT ID NCT02279004
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing a blood-based genetic test to find cancer-driving mutations in patients with lung cancer or melanoma. The goal is to see if this simple blood draw can replace the need for a tumor biopsy, which is slower and more invasive. Researchers will check how accurate the test is and whether it can track how well treatment is working over time. About 840 people are taking part.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
blood-based genetic test (ddPCR plasma genotyping assay)
What this could lead to
If successful, this blood test could provide a quicker, less invasive way to identify cancer mutations and monitor treatment response, helping doctors choose the right targeted therapy sooner.
What could go wrong
This is an observational study, not a treatment trial. The test may not be accurate enough to replace tumor biopsies in all cases, and results may not improve patient outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States